Neuroprotection against hypoxic/hypoglycaemic injury after the insult by the group III metabotropic glutamate receptor agonist (R, S)-4-phosphonophenylglycine
- PMID: 11030711
- PMCID: PMC1572399
- DOI: 10.1038/sj.bjp.0703646
Neuroprotection against hypoxic/hypoglycaemic injury after the insult by the group III metabotropic glutamate receptor agonist (R, S)-4-phosphonophenylglycine
Abstract
The role of group III metabotropic glutamate receptors (mGluR) in ischaemic neurodegeneration is still unsettled. In order to examine a possible modulatory effect of these receptors on ischaemia-induced damage we tested the novel selective agonist (R, S)-4-phosphonophenylglycine [(R,S)-PPG] after an hypoxic/hypoglycaemic insult in rat hippocampal slices. The recovery of population spike amplitudes in the CA1-region was used as parameter for neuronal viability. (R,S)-PPG significantly improved the recovery of synaptic transmission in the CA1-region even when applied only during the recovery period. The results imply that presynaptic glutamate release after an insult contributes to neurodegeneration. Since agonists of group III mGluR reduce neurotransmitter release - probably via presynaptic autoreceptors - we interpret the results obtained in our in vitro model of hypoxia/hypoglycaemia as support of the hypothesis that group III mGluR agonists might be beneficial drugs against diseases where excitotoxicity is one of the dominant pathological mechanisms.
Figures

Similar articles
-
Distinct influence of the group III metabotropic glutamate receptor agonist (R,S)-4-phosphonophenylglycine [(R,S)-PPG] on different forms of neuronal damage.Neuropharmacology. 2000 Mar 3;39(5):911-7. doi: 10.1016/s0028-3908(99)00256-7. Neuropharmacology. 2000. PMID: 10699457
-
(R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo.J Pharmacol Exp Ther. 1999 Jun;289(3):1678-87. J Pharmacol Exp Ther. 1999. PMID: 10336568
-
Influence of metabotropic glutamate receptor agonists on the inhibitory effects of adenosine A1 receptor activation in the rat hippocampus.Br J Pharmacol. 1997 Aug;121(8):1541-8. doi: 10.1038/sj.bjp.0701291. Br J Pharmacol. 1997. PMID: 9283686 Free PMC article.
-
Group III metabotropic glutamate receptors: guardians against excitotoxicity in ischemic brain injury, with implications for neonatal contexts.Pharmacol Rep. 2024 Dec;76(6):1199-1218. doi: 10.1007/s43440-024-00651-z. Epub 2024 Sep 17. Pharmacol Rep. 2024. PMID: 39298028 Free PMC article. Review.
-
Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection.Neuropharmacology. 1999 Oct;38(10):1477-84. doi: 10.1016/s0028-3908(99)00102-1. Neuropharmacology. 1999. PMID: 10530809 Review.
Cited by
-
Roles of metabotropic glutamate receptor 8 in neuropsychiatric and neurological disorders.Int Rev Neurobiol. 2023;168:349-366. doi: 10.1016/bs.irn.2022.10.003. Epub 2022 Nov 7. Int Rev Neurobiol. 2023. PMID: 36868634 Free PMC article. Review.
-
Modes of Neuronal Calcium Entry and Homeostasis following Cerebral Ischemia.Stroke Res Treat. 2010 Nov 1;2010:316862. doi: 10.4061/2010/316862. Stroke Res Treat. 2010. PMID: 21052549 Free PMC article.
-
Metabotropic glutamate receptors as targets for multipotential treatment of neurological disorders.Neurotherapeutics. 2009 Jan;6(1):94-107. doi: 10.1016/j.nurt.2008.10.038. Neurotherapeutics. 2009. PMID: 19110202 Free PMC article. Review.
-
Activation of group III metabotropic glutamate receptors attenuates rotenone toxicity on dopaminergic neurons through a microtubule-dependent mechanism.J Neurosci. 2006 Apr 19;26(16):4318-28. doi: 10.1523/JNEUROSCI.0118-06.2006. J Neurosci. 2006. PMID: 16624952 Free PMC article.
-
Family C G-Protein-Coupled Receptors in Alzheimer's Disease and Therapeutic Implications.Front Pharmacol. 2019 Oct 28;10:1282. doi: 10.3389/fphar.2019.01282. eCollection 2019. Front Pharmacol. 2019. PMID: 31719824 Free PMC article. Review.
References
-
- ABDUL-GHANI A., ATTWELL P.J.E., SING KENT N., BRADFORD H.F., CROUCHER M.J., JANE D.E. Anti-epileptogenic and anticonvulsant activity of L-2-amino-4-phosphonobutyrate, a presynaptic glutamate receptor agonist. Brain Res. 1997;755:202–212. - PubMed
-
- BIGGE C.F., DRUMMOND J.T., JOHNSON G., MALONE T., PROBERT A.W., JR, MARCOUX F.W., COUGHENOUR L.L., BRABES L.J. Exploration of phenyl-spaced 2-amino-(5-9)-phosphonoalkanoic acids as competitive N-methyl-D-aspartatic acid antagonists. J. Med. Chem. 1989;32:1580–1590. - PubMed
-
- BOND A., O'NEILL M.J., HICKS C.A., MONN J.A., LODGE D. Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia. NeuroReport. 1998;9:1191–1193. - PubMed
-
- BRUNO V., BATTAGLIA G., KINGSTON A., O'NEILL M.J., CATANIA M.V., DI GREZIA R., NICOLETTI F. Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4-carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors. Neuropharmacology. 1999;38:199–207. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous